Editas Medicine, Inc. (EDIT): who owns it and who trades it
As of Nov 16, 2026, EDIT insiders reported 16 open-market sales worth $177K and no purchases in the last 12 months, with 100% of the sale value made under pre-set 10b5-1 plans. The largest seller was Gilmore Neil O'Neill (CEO), with $131K. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Editas Medicine
From the latest filingsOverall: more buying than selling. Funds and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns EDIT
213 funds and institutions reported EDIT shares worth $392M at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is TCG Crossover Management, LLC with 11.3%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| TCG Crossover Management, LLC | 11.11M | 11.35% | $36M | – |
| BlackRock, Inc. | 10.59M | 10.82% | $34.3M | +14% |
| ADAR1 Capital Management, LLC | 8.89M | 9.08% | $28.8M | – |
| Ra Capital Management, L.P. | 8.89M | 9.08% | $28.8M | – |
| Commodore Capital LP | 8.89M | 9.08% | $28.8M | – |
| Vanguard Capital Management LLC | 6.14M | 6.27% | $19.9M | +46% |
| Paradigm Biocapital Advisors LP | 5.59M | 5.71% | $18.1M | – |
| Opaleye Management Inc. | 3.86M | 3.94% | $12.5M | +100% |
| Vanguard Portfolio Management LLC | 3.60M | 3.68% | $11.7M | +14% |
| Woodline Partners LP | 3.56M | 3.63% | $11.5M | – |
| Vivo Capital, LLC | 3.56M | 3.63% | $11.5M | – |
| GordonMD Global Investments LP | 3.13M | 3.19% | $10.1M | – |
| Goldman Sachs Group Inc | 2.61M | 2.67% | $8.5M | +368% |
| Geode Capital Management, LLC | 2.57M | 2.62% | $8.3M | +11% |
| Renaissance Technologies LLC | 2.47M | 2.52% | $8M | -38% |
| Logos Global Management LP | 2.22M | 2.27% | $7.2M | – |
| State Street Corp | 2.19M | 2.24% | $7.1M | +6% |
| Marshall Wace, LLP | 2.04M | 2.08% | $6.6M | +869% |
| D. E. Shaw & Co., Inc. | 1.90M | 1.94% | $6.2M | -2% |
| JPMorgan Chase & Co | 1.86M | 1.90% | $6M | – |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, EDIT insiders reported $0 of open-market purchases and $177K of sales. 100% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 11, 2026 | Linda Burkly | Vice president | Sale plan | 7,814 | $2.42 | $18.9K | Form 4 |
| Nov 11, 2026 | Gilmore Neil O'Neill | CEO | Sale plan | 21,164 | $2.42 | $51.1K | Form 4 |
| Sep 3, 2026 | Linda Burkly | Vice president | Sale plan | 709 | $3.04 | $2.2K | Form 4 |
| Sep 3, 2026 | Amy Parison | CFO | Sale plan | 453 | $3.04 | $1.4K | Form 4 |
| Sep 3, 2026 | Gilmore Neil O'Neill | CEO | Sale plan | 5,124 | $3.04 | $15.6K | Form 4 |
| Aug 3, 2026 | Amy Parison | CFO | Sale plan | 678 | $2.58 | $1.7K | Form 4 |
| Jul 28, 2026 | Linda Burkly | Vice president | Sale plan | 4,928 | $2.67 | $13.2K | Form 4 |
| Jun 3, 2026 | Amy Parison | CFO | Sale plan | 464 | $2.70 | $1.3K | Form 4 |
| Jun 3, 2026 | Gilmore Neil O'Neill | CEO | Sale plan | 15,380 | $2.70 | $41.5K | Form 4 |
| Jun 3, 2026 | Linda Burkly | Vice president | Sale plan | 731 | $2.70 | $2K | Form 4 |
| Mar 3, 2026 | Gilmore Neil O'Neill | CEO | Sale plan | 5,394 | $2.02 | $10.9K | Form 4 |
| Mar 3, 2026 | Amy Parison | CFO | Sale plan | 474 | $2.02 | $957 | Form 4 |
| Mar 3, 2026 | Linda Burkly | Vice president | Sale plan | 749 | $2.02 | $1.5K | Form 4 |
| Dec 3, 2025 | Linda Burkly | Vice president | Sale plan | 713 | $2.15 | $1.5K | Form 4 |
| Dec 3, 2025 | Gilmore Neil O'Neill | CEO | Sale plan | 5,603 | $2.15 | $12K | Form 4 |
| Dec 3, 2025 | Amy Parison | CFO | Sale plan | 461 | $2.15 | $991 | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Gilmore Neil O'Neill | CEO, Director | – | $131K | Nov 11, 2026 |
| Linda Burkly | EVP, CHIEF SCIENTIFIC OFFICER | – | $39.2K | Nov 11, 2026 |
| Amy Parison | SVP, Chief Financial Officer | – | $6.3K | Sep 3, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
EDIT short interest
Very high short interest. 25.2% of EDIT shares are sold short: about 1 share in 4. Over the last 12 reports the number of shares short went up 305%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 38.72M EDIT shares were sold short, 25.2% of the shares outstanding, up 1.4% from the report before. At the average daily volume of 2.20M shares, buying them all back would take about 17.6 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 38.72M | 25.21% | +1% | 2.20M | 17.6 |
| Oct 15, 2026 | 38.19M | 24.86% | +3% | 2.66M | 14.3 |
| Sep 30, 2026 | 37.11M | 24.16% | +24% | 3.97M | 9.3 |
| Sep 15, 2026 | 29.96M | 19.51% | -1% | 1.91M | 15.7 |
| Aug 31, 2026 | 30.23M | 19.69% | +22% | 3.37M | 9.0 |
| Aug 14, 2026 | 24.69M | 16.07% | +5% | 1.69M | 14.6 |
| Jul 31, 2026 | 23.46M | 15.28% | +6% | 1.29M | 18.2 |
| Jul 15, 2026 | 22.20M | 22.67% | -1% | 2.77M | 8.0 |
| Jun 30, 2026 | 22.47M | 22.95% | +22% | 3.12M | 7.2 |
| Jun 15, 2026 | 18.41M | 18.81% | +22% | 2.39M | 7.7 |
| May 29, 2026 | 15.07M | 15.39% | +58% | 4.48M | 3.4 |
| May 15, 2026 | 9.56M | 9.77% | -4% | 1.12M | 8.6 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Editas Medicine company events
Editas Medicine filed 12 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership, auditor). The latest was on Nov 9, 2026.
- Nov 9, 2026ResultsReleased financial results. Filing
- Oct 8, 2026AnnouncementThe Company announced that it has received approval to initiate the Phase 1/2 Strive™ clinical trial of EDIT-401 in patients with heterozygous familial hypercholesterolemia in Australia. Filing
- Aug 5, 2026LeadershipElliott Levy, M.D., a member of the Board of Directors of the Company who was serving as a class I director, resigned from the Board, effective August 4, 2026. Filing
- Jun 18, 2026VoteReported shareholder vote results. Filing
- May 26, 2026AgreementEditas Medicine, Inc. entered into an underwriting agreement with Cantor Fitzgerald & Co. and Wells Fargo Securities, LLC as representatives of the underwriters named therein, relating to an underwritten public offering of 55,555,556 shares of the Company’s common stock, $0.0001 par value per… Filing
- May 26, 2026AnnouncementEditas Medicine, Inc. notified TD Securities (USA) LLC that it was suspending and terminating the prospectus supplement, dated March 21, 2025, related to the sales agreement that the Company entered into with TD Cowen on May 14, 2021, as amended on February 28, 2024 and on March 5, 2025 (as… Filing
- May 26, 2026AnnouncementThe Company announced in an oral presentation at the 94 th European Atherosclerosis Society (EAS) Congress new preclinical data for EDIT-401, its lead in vivo development candidate, from preclinical studies in non-human primates. Filing
- May 14, 2026AnnouncementAt the 2026 Annual Meeting of the American Society of Gene and Cell Therapy, the Company reported new preclinical data supporting the continued advancement of the Company’s lead in vivo development candidate, EDIT-401, and its potential as a one-time treatment for hyperlipidemia, as well as the… Filing
- May 5, 2026ResultsReleased financial results. Filing
- Apr 7, 2026AuditorChanges in Registrant’s Certifying Accountant. Filing
- Mar 27, 2026AnnouncementThe U.S. Patent and Trademark Office reaffirmed the Patent Trial and Appeal Board’s previous decision favoring the Broad Institute in the U.S. patent interference involving specific patents for CRISPR/Cas9 editing in human cells between the University of California, the University of Vienna, and… Filing
- Mar 9, 2026ResultsReleased financial results. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Editas Medicine financials
Famous investors that hold EDIT
4 of the 50 well-known investors we track reported holding EDIT in their latest 13F filing. The largest position is Jim Simons's, worth $6.4M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jim Simons · Renaissance Technologies | Q3 2026 | 2.50M | $6.4M | 0.0% | +1% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 512,506 | $1.3M | 0.0% | +309% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 234,312 | $602K | 0.0% | +10% |
| Israel Englander · Millennium Management | Q3 2026 | 211,484 | $544K | 0.0% | -58% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named EDIT in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Oct 27, 2026 | BlackRock, Inc. | 13G | 7.8% |
| Oct 27, 2026 | BlackRock, Inc. | 13G | 7.8% |
Questions about Editas Medicine, Inc. (EDIT) stock
Who owns the most EDIT stock?
The largest reported owner of Editas Medicine, Inc. (EDIT) is TCG Crossover Management, LLC, with 11.3% of the company. In total, 213 funds and institutions reported holding EDIT at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are EDIT insiders buying or selling?
In the last 12 months, EDIT insiders reported no open-market purchases and 16 sales worth $177K. The latest trade was on Nov 11, 2026. See every trade.
What is the short interest in EDIT?
As of Oct 30, 2026, 38.72M EDIT shares were sold short, 25.2% of the shares outstanding, up 1.4% from the report before. At the average daily volume of 2.20M shares, buying them all back would take about 17.6 trading days (days to cover). See the history.
Which famous investors hold EDIT?
4 of the 50 well-known investors we track reported EDIT in their latest 13F filing, including Jim Simons, Steve Cohen, Ken Griffin. The largest position is worth $6.4M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.